Dashyant Dhanak
CIK 1760682 · EVP & Chief Scientific Officer · last filed 2024-06-11
Dashyant Dhanak is an EVP & Chief Scientific Officer who has filed 42 SEC Form 4 insider transactions across 2 companies since 2018. The most recent filing, for DCPH, was dated Jun 11, 2024. Across all open-market trades the lifetime net is −$1.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.8M across reported positions. 40 SEC filings were submitted jointly with INCYTE CORP.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
INCY price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1801 AUGUSTINE CUT-OFF
WILMINGTON, DE 19803
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | EVP & Chief Scientific Officer | 0 | $25.59 | $0 | $0 | 3 | 2024-06-11 |
| INCY | EVP & Chief Scientific Officer | 58,968 | $116.11 | $6.85M | -$1.87M | 39 | 2023-07-18 |
Recent Filings
42 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-11 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Mixed | −158,175 | $0 | EDGAR |
| 2024-02-20 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Grant (A) | +17,275 | $0 | EDGAR |
| 2023-09-19 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Grant (A) | +140,900 | $0 | EDGAR |
| 2023-07-18 | INCY | Grant (A) | +8,056 | $0 | EDGAR |
| 2023-07-06 | INCY | Tax (F) | −6,044 | -$375.2K | EDGAR |
| 2023-02-21 | INCY | Exer (M) | +3,693 | $241.6K | EDGAR |
| 2023-01-30 | INCY | Sell (S) | −2,419 | -$205.6K | EDGAR |
| 2023-01-24 | INCY | Grant (A) | +4,980 | $0 | EDGAR |
| 2022-12-13 | INCY | Tax (F) | −533 | -$43.9K | EDGAR |
| 2022-07-06 | INCY | Mixed | +9,093 | -$172.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.